LAUSR

Melanoma is a highly aggressive tumor derived from melanocytes. In recent years, the incidence and mortality of melanoma have gradually increased, seriously threatening human health. Classic treatments like surgery, chemotherapy, and radiotherapy show very limited efficacy. Due to the high immunogenicity of melanoma cells, immune checkpoint inhibitors have received considerable attention as melanoma treatments. One such therapy is blockade of programmed cell death‐1 (PD‐1), which is one of the most important negative immune regulators and is mainly expressed on activated T cells. Disruption of the interactions between PD‐1 and its ligands, programmed death‐ligand 1 (PD‐L1) or programmed death‐ligand 2 (PD‐L2) rejuvenates exhausted T cells and enhances antitumor immunity. Although PD‐1 blockade therapy is widely used in melanoma, a substantial proportion of patients still show no response or short durations of remission. Recent researches have focused on revealing the underlying mechanisms for resistance to this treatment and improving its efficacy through combination therapy. Here, we will introduce the resistance mechanisms associated with PD‐1 blockade therapy in melanoma and review the combination therapies available.